“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

19 March 2019
Pharma

Visiongain has published a new pharma report Global Asthma & COPD Therapies Market 2019-2029: Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period.

Despite approaching maturity, there remain several unmet needs in the market. In particular, COPD has long been ignored both by medical practitioners, the general public and also the pharmaceutical industry. As the disease is predicted to become the third-leading cause of death by 2030, this will be an area in which novel therapeutics may bring in significant revenue.

The asthma market is becoming highly competitive and fragmented, but there remain significant areas with unmet needs. Pharmaceutical companies will depend on life cycle management strategies in the immediate future to maintain profits with newer pipeline products becoming available over the forecast period.

The lead analyst commented that "Recent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed. The studies suggest that varying genotypes and phenotypes lead to different patients reacting differently to the same drug. This will drive demand for personalised therapies targeting the needs of each patient subgroup. Drugs paired with tests for biomarkers could become more frequent in the R&D pipeline going forward."

Leading companies featured in this report include AstraZeneca, Boehringer Ingelheim, GSK, Merck, Novartis, Roche, Teva and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read